Jacobio’s cancer treatment given breakthrough therapy designations by China CDE
Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China.…
December 19, 2022 - 2 minutes
Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China.…